Dulaglutide vs Mod GRF 1-29

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Dulaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.

Full details →

Mod GRF 1-29

Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.

Full details →

Side-by-Side Comparison

Aspect	Dulaglutide	Mod GRF 1-29
Dose Range	750 mcg–4.5 mg	100 mcg–200 mcg
Frequency	Less than daily	3x daily
Cycle Length	12–52 weeks	8–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression.	Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity.
Typical Dosage	Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response.	Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects.
Administration	Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens.	Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version.
Side Effects	Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration.	Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention.
Best For	Fat Loss	Muscle Growth Fat Loss Recovery & Healing Sleep Quality